Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

Filter

May 2024 | From Akero Therapeutics

FGF21 Agonists: An Emerging Therapeutic for Metabolic Dysfunction-Associated Steatohepatitis and Beyond

Mar 2024 | From Akero Therapeutics

Efruxifermin significantly improved collagen biomarkers, consistent with beneficial ECM remodeling in patients with F2-F3 fibrosis due to MASH

Mar 2024 | From Akero Therapeutics

Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study

Feb 2024 | From Akero Therapeutics

Decreases in liver cT1 accurately reflect histological improvement induced by therapies in MASH: a multi-centre pooled cohort analysis

Nov 2023 | From Akero Therapeutics

Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist (GLP-1RA) in Patients with NASH/MASH and T2D: a Randomized, Placebo-controlled Study (Cohort D)

Oct 2023 | From Akero Therapeutics

Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebocontrolled, phase 2b trial

Jun 2023 | From Akero Therapeutics

Noninvasive tests of liver injury, inflammation and fibrosis are improved by efruxifermin and correlate with histological improvements in patients with F2-F3 NASH: secondary analysis of Ph2b HARMONY study

We are evaluating potential treatments for MASH and other serious metabolic diseases to build our pipeline.

We are evaluating potential treatments for MASH and other serious metabolic diseases to build our pipeline.